



Nitro derivatives and other compounds from sugar apple (*Annona squamosa* L.) leaves exhibit soluble epoxide hydrolase inhibitory activity

Hong Xu Li¹ · Seo Young Yang¹ · Young Soo Kim² · Hae Dong Jang³ · Young Ho Kim¹ · Wei Li²

Received: 31 May 2019 / Accepted: 14 August 2019 / Published online: 24 August 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

A phytochemical study for the MeOH extract of *Annona squamosa* leaves led to the isolation of seven compounds. Among them there were two nitro derivative compounds (**1** and **2**), two phenolic glucoside compounds (**3** and **4**), and three sesquiterpenes (**5–7**). The structures of these natural compounds were determined by the spectroscopic methods including 1D and 2D NMR methods. All the isolated compounds were assessed for the effects on the sEH inhibitory activity; of all the compounds, thalictoside (**1**) and arabinothalictoside (**2**) displayed strong inhibition of sEH activities with IC₅₀ value of 20.2 μM and 47.1 μM, respectively. A kinetic analysis of compounds **1** and **2** revealed that both of them were competitive inhibitory action. The molecular docking increases our understanding of receptor–ligand binding of all compounds. These results suggested that nitro derivatives from *Annona squamosa* leaves are potential sEH inhibitors.

Keywords *Annona squamosa* L. · Molecular docking · Nitro derivative · Soluble epoxide hydrolase (sEH)

Introduction

Annona squamosa L. (Annonaceae) is commonly known as sugar apple, custard apple, or sweetsop, with a long history of traditional usage, which in recent years has been cultivated in tropical and subtropical regions worldwide. Different portions of *A. squamosa* revealed various phytochemicals and constituents including alkaloids,

terpenes, flavonoids, annonaceous acetogenins, cyclopeptides, and essential oils (Ma et al. 2017; Soni et al. 2012). The long history of usage with *A. squamosa* L. could suggest a vast natural product source of active phytochemical constituents. Many studies of extractions and fractions revealed significant potential of anti-cancer (Kim et al. 1998; Mazahery et al. 2009), anti-diabetic and hypolipidemic (Kaleem et al. 2006; Kaleem et al. 2008), antioxidant (Panda and Kar 2015), and anti-hypertensive (Morita et al. 2006) properties. Nonetheless, previous literatures reported ~150 compounds from different portions of *A. squamosa*; most of them were isolated from the seeds and ~14 compounds were isolated from the stem and leaves, the majority of which were aporphine alkaloids. Therefore, the phytochemical investigation for the leaves of *A. squamosa* needs to be studied further.

Soluble epoxide hydrolase (sEH) is widely distributed in mammalian tissues, with potent biological activities on cardiovascular and urinary systems (Campbell et al. 1996). It is responsible for the hydrolysis of epoxyeicosatrienoic acids (EETs), which are endothelium-derived hyperpolarizing factors (EDHFs) that act as regulators of vascular function (Imig and Hammock 2009). The sEH can convert EETs to its corresponding diols (dihydroxyeicosatrienoic acids) and reduce EET effects on cardiovascular systems

These authors contributed equally: Hong Xu Li, Seo Young Yang

Supplementary information The online version of this article (<https://doi.org/10.1007/s00044-019-02425-2>) contains supplementary material, which is available to authorized users.

✉ Young Ho Kim
yhk@cnu.ac.kr

✉ Wei Li
liwei1986@kiom.re.kr

¹ College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea

² Korean Medicine (KM) Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Republic of Korea

³ Department of Food and Nutrition, Hannam University, Daejeon 305-811, Republic of Korea

through vasodilation, anti-migration of vascular smooth muscle cells, and anti-inflammatory actions. Therefore, sEH was considered a potential therapeutic target for vascular disease (Bai et al. 2015). However, the components from *A. squamosa* exhibited vasorelaxant effect (Morita et al. 2006); nevertheless, sEH inhibitory activities for the components of *A. squamosa* have not been reported.

Materials and methods

Plant material

Dried leaves of *A. squamosa* were kindly provided from Chung Kim, Danang, Vietnam, in 2015. Its scientific name was identified by one author (Professor Young Ho Kim). A voucher specimen (CNU 15003) was deposited at the Herbarium of College of Pharmacy, Chungnam National University, Republic of Korea.

General experimental procedures

The nuclear magnetic resonance (NMR) spectra were recorded using a BRUKER AVANCE III 600 (^1H , 600 MHz; ^{13}C , 150 MHz) (Bruker Biospin GmbH, Karlsruhe, Germany), with tetramethylsilane as an internal standard. Heteronuclear multiple quantum correlation, heteronuclear multiple bond correlation, rotating frame nuclear overhauser effect spectroscopy, and ^1H – ^1H correlation spectroscopy spectra were recorded using a pulsed field gradient. The high-resolution electrospray ionization mass spectrometry (MS) spectra were obtained by using an Agilent 1200 LC-MSD Trap spectrometer (Agilent, Santa Clara, CA, USA). Preparative high-performance liquid chromatography (HPLC) was performed using a GILSON 321 pump, 151 UV/VIS detector (Gilson, VILLIERS-LE-BEL, France), and RStech HECTOR-M C_{18} column (5 μm , 250 \times 21.2 mm) (RS Tech Crop, Chungju, South Korea). Column chromatography was performed using a silica gel (Kieselgel 60, 70–230, and 230–400 mesh, Merck, Darmstadt, Germany) and YMC C-18 resins, and thin layer chromatography was performed using pre-coated silica-gel 60 F_{254} and RP-18 $\text{F}_{254\text{S}}$ plates (both 0.25 mm, Merck, Darmstadt, Germany); the spots were detected under UV light using 10% H_2SO_4 .

Extraction and isolation

The dry leaves of *A. squamosa* (2.0 kg) was reflux extracted with MeOH (5 L \times 3 times). The total extraction (300 g) of MeOH was suspended in deionized water and partitioned with Hexane and water fraction. Then the water fraction was partitioned sequentially with EtOAc and BuOH,

yielding EtOAc (1A, 12.2 g) and BuOH (1B, 60.5 g). The BuOH fraction was subjected to a silica gel column chromatography with a gradient of CHCl_3 -MeOH- H_2O (10:1:0, 9:1:0, 8:1:0, 6:1:0.1, 5:1:0.1, 4:1:0.1, 3:1:0.1, and 2:1:0.1, MeOH, 5 L for each step) to give 11 fractions (Fr. 1B-1–1B-11). Fraction 1B-2 was isolated with a gradient of MeOH- H_2O (1:4, 1:3, 1:2, and 1:1 MeOH) by middle-pressure liquid chromatography using YMC C_{18} column to give eight fractions (Fr. 1C-1–1C-8). The fraction 1C-2 was separated by a Sephadex LH-20 column and eluted by MeOH, and its subfraction was isolated by prep-HPLC to give compound **1** (40.0 mg) and compound **3** (13.3 mg). The fraction 1C-3 was separated by a Sephadex LH-20 column and eluted by MeOH, and its subfractions were isolated by prep-HPLC to give compound **2** (23.2 mg). The fraction. 1C-4 was separated by a Sephadex LH-20 column and eluted by MeOH, and its subfraction was isolated by prep-HPLC to give compound **5** (24.0 mg). The fraction 1C-5 was separated by a Sephadex LH-20 column and eluted by MeOH, and its subfraction was isolated by prep-HPLC to give compound **4** (13.5 mg). The fraction 1C-6 was separated by a Sephadex LH-20 column and eluted by MeOH, and its subfraction was isolated by prep-HPLC to give compound **6** (9.1 mg). The fraction 1C-7 was separated by a Sephadex LH-20 column and eluted by MeOH, and its subfraction was isolated by prep-HPLC to give compound **7** (4.6 mg).

sEH assay

sEH activity assay

In sEH inhibitory assay, Bis-Tris (B9754) and albumin (A8806) were purchased from Sigma Aldrich (St. Louis, MO, USA). Human recombinant sEHs (10011669) and 3-phenyl-cyano (6-methoxy-2-naphthalenyl) methyl ester-2-oxiraneacetic acid (PHOME) (10009134) were purchased from Cayman Chemical (Cayman, MI, USA). Ninety-six-well white plate was purchased from Costar (Corning, NY, USA). Fluorescence intensity measurement was conducted on using Tecan infinite F200 microplate reader (Tecan, Mannedorf, Switzerland).

The enzymatic assays were performed according to methods modified from previous study (Bai et al. 2015). The 130 μL aliquot of recombinant human sEH (12.15 ng/mL) was diluted with buffer (25 mM Bis-Tris-HCl, pH 7.0 containing 0.1 mg/mL bovine serum albumin (BSA)) and mixed with 20 μL of MeOH, and then 50 μL of PHOME (10 μM) was added. The amount of product converted from substrate by the enzyme was measured by fluorescence photometry (excitation filter 330 nm and emission filter 465 nm) as follows: enzyme activity (%) = $[S_{40} - S_0/C_{40} - C_0] \times 100$. Where C_{40} and S_{40} are the fluorescence of control

and inhibitor after 40 min, and S_0 and C_0 are the fluorescence of inhibitor and control at 0 min. In this testing, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) was used as a positive control.

sEH kinetic assay

Kinetic assays were determined under steady-state condition as described. Buffer, incubation times, and enzyme concentrations were specific for each single nucleotide polymorphism to achieve detectable product formation. The enzyme inhibition properties of these components were modeled using double-reciprocal plots (Lineweaver–Burk and Dixon analyses). In brief, 50 μL of sEH and 20 μL of various concentrations of the compounds dissolved in MeOH were added in 96-well plate containing 80 μL of 25 mM bis-Tris–HCl buffer (pH 7.0) containing 0.1% BSA and then mixed with 50 μL of range of 5–80 μM PHOME as a substrate. After starting the enzyme reaction at 37 $^\circ\text{C}$, products by hydrolysis of the substrate were monitored at excitation and emission of 330 and 465 nm during 30 min (Kim et al. 2014).

Molecular docking

The three-dimensional (3D) structure of the ligand was modeled and minimized by MM2 using Chem 3D Pro. (version: 17.0). The flexible bonds of ligands were assigned with Autodock Tools. The sEH structure (PDB ID: 3ANS) was downloaded from research collaboratory for structural bioinformatics (RCSB) (protein data bank), after ligands were removed from the original sEH using Chimera. All hydrogen atoms and gasteiger charges in the protein structures were added using Autodock Tools. Simulation studies were performed using the Autodock 4.2 version program according to the instructions on the Autodock Homepage (<http://autodock.scripps.edu/>). In brief, to perform docking in Autodock 4.2, the grid dimensions were established to contain all the enzyme (for the blind docking) with packing (0.375 \AA). Docking simulation of protein structures and


building new ligands were performed using the Lamarckian Genetic Algorithm and runs 30 number. Finally, the maximum number of evals was set as long and then the docking scores were calculated.

Results and discussion

Seven compounds were isolated from the MeOH extract of *A. squamosa* (Fig. 1). Their structures were identified as thalictoside (1) (Wang et al. 2017), arabinothalictoside (2) (Yoshikawa et al. 1996), benzyl-*O*- β -D-glucopyranoside (3) (Zeng et al. 2011), icariside F₂ (4) (Bai et al. 2015), austroside A (5) (Wang et al. 2005), staphylioside D (6) (Hisamoto et al. 2004), and icariside B₁ (7) (Hisamoto et al. 2004). Their structures were elucidated by one- and two-dimensional NMR and MS. In this study, to the best of our knowledge, for the first time 2–6 were isolated from the Annonaceae family, and 1 and 7 were isolated from the species of *A. squamosa* L.

We investigated the sEH inhibitory effect of the isolated compounds (1–7) from *A. squamosa* L. The sEH inhibitory activities were determined using recombinant human sEH incubated with PHOME, an artificial substrate for fluorescence detection (Table 1). All the isolated compounds were tested against 100 μM sEH. Compounds 1 and 2 exhibited sEH inhibitory effect with 78.6% and 55.8%, respectively, whereas other compounds revealed no inhibitory activity. From the previous reports, these two nitro derivatives were rarely studied. However, thalictoside (1) was considered as an active component for anti-osteoporosis (Xu et al. 2016). To our surprise, the monosaccharide and disaccharide of nitro derivatives displayed with dramatic difference of IC₅₀ values according to the various glycon numbers for onefold for 1 with 20.2 μM and 2 with 41.9 μM . Such results indicated that not merely the nitro moiety has strong inhibition effects for sEH but also the numbers of glycon could influence the inhibitory activity, which indicated that the more glycons the less inhibitory activity. However, 3 and 4 were also phenolic compounds connected with a

Fig. 1 Structures of compounds 1–7 from *A. squamosa*



monosaccharide and a disaccharide with similar sEH inhibitory activities for 44.4% and 44.9%, respectively. The results above suggested that the nitro moieties were crucial

Table 1 Inhibitory effects of isolated compounds **1–7**

Inhibition of compounds on sEH			
Compounds	100 μM (%)	IC ₅₀ (μM)	Type (K_i , μM)
1	78.6 \pm 0.8	20.2 \pm 0.2	Competitive (7.3 \pm 0.4)
2	55.8 \pm 0.6	41.9 \pm 2.1	Competitive (14.1 \pm 0.9)
3	44.4 \pm 6.0	NT	NT
4	44.9 \pm 0.1	NT	NT
5	44.0 \pm 0.4	NT	NT
6	45.5 \pm 1.5	NT	NT
7	40.4 \pm 3.3	NT	NT
AUDA ^a		16.7 \pm 0.6	

sEH activity was expressed as the percentage of control activity

Values represent means \pm SD ($n = 3$)

NT not tested

^aPositive control

for the sEH inhibitory activities, despite the different glycon numbers substituted with the phenolic compound. Nonetheless, the sesquiterpene-type compounds were different in structures but the sEH inhibitory activity results were similar, with the results of 44.0%, 45.5%, and 40.4% for **5**, **6**, and **7**, respectively. The results suggested such sesquiterpene compounds were trivial for the sEH inhibitory activity.

Since AUDA completed clinical trial for heart failure in 2012, tremendous difficulties have been faced in obtaining Food and Drug Administration approval for sEH inhibitors evaluated in completed clinical trials (Tran et al. 2012). The recent studies for sEH inhibitors have more attention on the nitro derivatives (Wagner et al. 2017; Zariello et al. 2019). The candidate inhibitory compounds (**1** and **2**) were analyzed in an enzyme kinetic study to access the binding mode between the receptor and ligands. The enzyme inhibition properties of these nitro derivatives were modeled via double-reciprocal plots (Lineweaver–Burk and Dixon analyses). The Lineweaver–Burk plot analysis suggested that increasing the inhibitor concentration increased the




Fig. 2 Study of binding mechanism between compounds **1** and **2**, and sEH: **a**, **c** Lineweaver–Burk plots for the inhibition of compounds **1** and **2**, respectively; **b**, **d** Dixon plots for compound **1** and **2**,

respectively. Data are the mean of three experiments carried out in triplicate and were determined by one-way analysis of variance followed by Dunnett's multiple comparison test, $P < 0.05$ vs. control




Fig. 3 Docking pose of compounds **1** and **2** into the predicted binding site of sEH

Table 2 Hydrogen bonding between sEH compounds **1**, **2**, and AUDA

Compounds	Receptor ^a (Å)	Autodock score (kcal/mol)
AUDA ^b	Asp105(2.80), Pro141(2.82), Tyr153(2.72), Gln154(3.03), Tyr236(2.74),	−8.8
1	Gln154(3.15), Ser185(2.99), Phe267(3.19), Trp295(3.19), Tyr236(3.16)	−8.4
2	Leu178(2.61), Arg180(3.09), Phe267(3.27), Trp295(3.04)	−8.2

^aAmino acid sequence number of receptors

^bPositive control

K_m values without changing the V_m values (Cleland 1963). Both the intercepts on the positive axis indicated that compounds **1** and **2** were competitive inhibitors. The K_i values for compounds **1** and **2** were calculated by Dixon plots, given the K_i values for 7.3 and 14.1 μM , respectively (Fig. 2).

A blind docking system was used to determine the enzyme sequences using the program Autodock 4.2. The results obtained from 30 docking runs suggested a reliable complex with a low Autodock score. Compounds **1** and **2** bounded to their predicted binding sites, which were considered allosteric sites (Fig. 3). The Autodock scores for AUDA, **1**, and **2** were −8.8, −8.4, and −8.2 kcal/mol (Table 2), respectively. Compounds **1** and **2** bounded the same target sites and participated in hydrogen bond with Phe267 and Trp295, whereas compound **1** and AUDA participated in hydrogen bond with Gln154 and Tyr236. Such bounding sites indicated that these amino acid sequences might be crucial receptors for nitro derivatives to inhibited sEH enzyme activities. In other sites, there were

Asp105, Pro141, Tyr153, Ser185, Leu178, and Arg180 between AUDA, **1**, and **2**.

Conclusions

In this study, seven compounds (**1**–**7**) were isolated from the MeOH extract of *A. squamosa*. The sEH inhibitory effect suggested that the nitro derivative components have potential biological activities on cardiovascular and urinary system, with **1** and **2** exhibiting 78.6% and 55.8% sEH inhibitory effect, respectively. However, the phytochemistry research was limited with n-BuOH fraction. For further study with *A. squamosa*, the nitro derivative components could serve as target compounds to investigate both phytochemistry and sEH inhibitory mechanism on cardiovascular and urinary system.

Acknowledgements This research was supported by a grant [KSN1812160] awarded to Korean Institute of Oriental Medicine by

the Ministry of Education, Science, and Technology (MEST), Republic of Korea.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Bai MM, Shi W, Tian JM et al. (2015) Soluble epoxide hydrolase inhibitory and anti-inflammatory components from the leaves of *Eucommia ulmoides* Oliver (Duzhong). *J Agric Food Chem* 63:2198–2205
- Campbell WB, Gebremedhin D, Pratt PF et al. (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. *Circ Res* 78:415–423
- Cleland WW (1963) The kinetics of enzyme-catalyzed reactions with two or more substrates or products: III. Prediction of initial velocity and inhibition patterns by inspection. *Biochim Biophys Acta* 67:188–196
- Hisamoto M, Kikuzaki H, Nakatani N (2004) Constituents of the leaves of *Peucedanum japonicum* Thunb and their biological activity. *J Agric Food Chem* 52:445–450
- Imig JD, Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. *Nat Rev Drug Discov* 8:794
- Kaleem M, Asif M, Ahmed QU et al. (2006) Antidiabetic and antioxidant activity of *Annona squamosa* extract in streptozotocin-induced diabetic rats. *Singap Med J* 47:670–675
- Kaleem M, Medha P, Ahmed QU et al. (2008) Beneficial effects of *Annona squamosa* extract in streptozotocin-induced diabetic rats. *Singap Med J* 49:800
- Kim GS, Zeng L, Alali F et al. (1998) Muricoreacin and murihexocin C, mono-tetrahydrofuran acetogenins, from the leaves of *annona muricata* in honour of professor GH Neil Towers 75th birthday. *Phytochemistry* 49:565–571
- Kim JH, Ryu YB, Lee WS et al. (2014) Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from *Corydalis turtschaninovii* rhizome. *Bioorg Med Chem* 22:6047–6052
- Mazahery ARF, Dator RP, Concepcion GP et al. (2009) Murihexocin C from the leaves of *Annona squamosa* Linn. induces apoptosis in human colon carcinoma Col 2 cell line. *Philos Agric Sci* 92:122–132
- Ma C, Chen Y, Chen J et al. (2017) A review on *Annona squamosa* L.: phytochemicals and biological activities. *Am J Chin Med* 45:933–964
- Morita H, Iizuka T, Choo CY et al. (2006) Vasorelaxant activity of cyclic peptide, cyclosquamosin B, from *Annona squamosa*. *Bioorg Med Chem Lett* 16:4609–4611
- Panda S, Kar A (2015) Protective effects of 5, 7, 4'-trihydroxy-6, 3'-dimethoxy-flavone 5-O- α -l-rhamnopyranoside, isolated from *Annona squamosa* leaves in thyrotoxicosis and in hepatic lipid peroxidation in rats. *Bioorg Med Chem Lett* 25:5726–5728
- Soni VK, Yadav DK, Bano N et al. (2012) N-methyl-6, 7-dimethoxyisoquinolone in *Annona squamosa* twigs is the major immune modifier to elicit polarized Th1 immune response in BALB/c mice. *Fitoterapia* 83:110–116
- Tran L, Kompa AR, Wang BH et al. (2012) Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients. *Cardiovasc Ther* 30:295–300
- Wagner KM, McReynolds CB, Schmidt WK et al. (2017) Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. *Pharm Ther* 180:62–76
- Wang HM, Kao CL, Liu CM et al. (2017) Chemical constituents of the roots of *Pluchea indica*. *Chem Nat Compd* 53:736–737
- Wang J, Shen Y, He H et al. (2005) Norsesquiterpenoid and sesquiterpenoid glycosides from *Evodia austrosinensis*. *Planta Med* 71:96–98
- Xu F, Ding Y, Guo Y et al. (2016) Anti-osteoporosis effect of *Epi-medium* via an estrogen-like mechanism based on a system-level approach. *J Ethnopharmacol* 177:148–160
- Yoshikawa M, Yoshizumi S, Murakami T et al. (1996) Medicinal foodstuffs. II. On the bioactive constituents of the tuber of *Sagittaria trifolia* L. (Kuwai, Alismataceae): absolute stereostructures of trifoliones A, B, C, and D, sagittariosides a and b, and arabinothalictoside. *Chem Pharm Bull* 44:492–499
- Zarriello S, Tuazon J, Corey S et al. (2019) Humble beginnings with big goals: small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders. *Prog Neurobiol* 172:23–39
- Zeng Q, Chang R, Qin J et al. (2011) New glycosides from *Dracocephalum tanguticum* maxim. *Arch Pharmacol Res* 34:2015–2020